
ASC2ESCALATE Clinical Trial in CML: Asciminib Dose Escalation Strategy
The ASC2ESCALATE trial (NCT05384587) is a single-arm study investigating asciminib (Scemblix) in both the first-line and second-line treatment of chronic myeloid leukemia (CML). In an interview with Targeted OncologyTM, David Andorsky, MD, oncologist at …